Changing Anti-Retroviral Therapy
description
Transcript of Changing Anti-Retroviral Therapy
Changing Anti-Retroviral Therapy
2
Introductory Case: Mikael
Mikael is a 28 year-old male diagnosed with AIDS who has been taking his triple drug ART regularly for the past 6 months without difficulties. He began therapy one year ago, during a bout of PCP pneumonia and oral thrush
CD4/TLC and VL monitoring is not available in his region
Today Mikael is diagnosed with toxoplasmosis and is hospitalized for treatment with Fansidar
3
Introductory Case: Mikael (cont.)
Which of the following statements about changing therapy are true?1. ART should not be changed because this patient is not
experiencing side effects from his regimen
2. A change in ART should be done for a patient who experiences a new opportunistic infection on ART
3. ART should be changed as soon as a patient starts to miss doses to avoid treatment failure
4. ART should only be changed when a patient experiences virologic failure
4
Unit Learning Objectives
Identify reasons for changing ART List factors in ART failure Determine how to change ART due to toxicity,
treatment failure or concomitant disease Describe factors to consider when changing ART Describe appropriate laboratory monitoring
procedures for ART
5
Factors to Consider When Changing Regimen
Ethiopia ARV guidelines Prior antiretroviral history Antiretroviral resistance Side effects Number of drugs needing
replacement
Barriers to adherence Patient life-style and
preferences Ability to follow-up in clinic Drug interactions Cost and sustainability
6
Reasons for Changing ART
ART is not changed unless absolutely necessary! ART may be changed because of:
Treatment Failure• Clinical failure
• Immunologic failure
• Virologic failureToxicity or intoleranceCo-morbid conditions Non-adherence/compromised quality of life
7
Treatment Failure
Treatment failure is defined byClinical failure
• New or recurrent OI
• Onset or recurrent WHO Stage III conditionNote: Should not be confused with immune reconstitution inflammatory
syndrome
Immunologic failure• Fall of CD4 count by >50% from the peak
• Return of the CD4 count to baseline or below
8
Introductory Case: Mikael (cont.)
1. ART should not be changed because this patient is not experiencing side effects from his regimen
FALSE Where CD4 counts and viral load tests are unavailable,
the WHO recommends using clinical evaluation to define treatment failure
This patient is experiencing clinical failure defined as the development of a new opportunistic infection (in this case toxoplasmosis) while on ART
9
Introductory Case: Mikael (cont.)
2. A change in ART should be done for a patient who experiences a new opportunistic infection on ART
TRUE
Where CD4 counts and viral load tests are unavailable, the WHO recommends using clinical evaluation to define treatment failure
10
Treatment Failure (2)
Virologic failure:Failure to suppress viral load to undetectableReappearance of detectable virus after a period of
undetectability (loss of virologic control)Less than one log (10-fold) decrease in viral load from
baseline after 8-12 weeks of ART
11
Antiretroviral Therapy: Failure to Suppress
Courtesy of David H. Spach, MD; NW AETC, University of Washington
10
100
1000
10000
100000
HIV
RN
A
Medications Started
50 50 TIME
12
Antiretroviral Therapy: Viral Failure
10
100
1000
10000
100000
HIV
RN
A
Medications Started
50 50 TIME
Courtesy of David H. Spach, MD; NW AETC, University of Washington
13
Reasons Treatment May Fail
Treatment fails if:Drugs are not strong enough to control the virusPatient is too sick (clinical failure) or has serious infections
which are not treatablePatient has poor adherence
• Missing more than three doses/month increases risk of treatment failure
• Missing additional doses causes drug levels to fall, making HIV resistant
14
Treatment Failure and IRIS
Must differentiate treatment failure from Immune Reconstitution Inflammatory Syndrome (IRIS)Clinical manifestation of a sub-clinical infection
present at baseline. Brought on by ART-induced reconstitution of the immune system
Typically seen within several weeks of initiating ART
15
Introductory Case: Mikael (cont.)
3. ART should be changed as soon as a patient starts to miss doses to avoid treatment failure
FALSE If it is determined that a patient is missing doses, it is best
to try to determine the cause and to identify a solution to assist the patient with adherence
Changing ART should only be done when absolutely necessary
16
Reasons Treatment May Fail (2)
Other medicines may stop ART from workingReduce levels of ARVs in the blood
• e.g. TB drug rifampicin is a potent liver enzyme inducer
Important: Patients must be warned that herbal medicines could
reduce ARV drug levelsTraditional healers must be told that their medicines could
reduce ARV drug levels
17
Reasons Treatment May Fail (3)
Patient cannot tolerate the available drugsLiver damage, nerve damage and anemia are possible
serious side effectsDiarrhea, nausea and vomiting caused by the drugs may
sometimes be too much to bearTreatment may have to be stopped if these side effects
become serious and replacement drugs are not available
18
Introductory Case: Mikael (cont.)
4. ART should only be changed when a patient experiences virologic failure
FALSE Virologic failure is only one possible reason that a change in therapy
may be necessary Other reasons to change therapy include:
• Intolerable toxicities or side effects• Treatment failure (clinical failure or immunologic failure)• Co-morbidities
19
Causes of ART Failure: Summary
Pre-existing Resistance
Limited Potency of Regimen
Imperfect Adherence
Poor Absorption
Rapid Elimination
Drug-Drug Interactions
Drug Failure
Persistent Viral Replication
20
Toxicity
About 50% of patients treated for three years with good viral suppression will require a change in therapy due to an adverse reaction to antiretroviral drugsIntolerable side effects
Organ Dysfunction
Interventions:If the offending drug can be identified, replace just that drug
If the offending drug cannot be identified, replace entire regimen
21
Clinical Indications to Change ART Due to ToxicitySymptom Clinical Indication
Nausea Severe discomfort or minimal intake for > 3 days
Vomiting Severe vomiting of all foods/fluids in 24 hrs, orthostatic hypotension or need of IV fluids
Diarrhea Bloody diarrhea, orthostatic hypotension or need of IV fluids
Fever Unexplained fever of > 39.6 C
Headache Severe or requires narcotics
Allergic Reaction
Generalized urticaria, angioedema or anaphylaxis
Peripheral Neuropathy
Severe discomfort, objective weakness, loss of 2-3 previously present reflexes or sensory dermatomes
Fatigue Normal activity reduced > 50%
22
Lab Indications to Change ART Due to ToxicityParameter Grade 3 Toxicity Normal Reference Values
Hematology
Hemoglobin (Hgb) < 7.0 g/dL M: 13.8 – 17.2 g/dLF: 12 – 15.6 g/dL
ANC < 750/mm3 1500 to 7000/mm3
Platelet count < 49 x 103/µL 130-400 x 103/µL
Chemistries
Total Bilirubin > 3-7.5 x ULN*= 3.9-9.75mg/dL
≤ 1.3 mg/dL
SCr > 1.7-2.0 (adult) ≤ 1.2 mg/dL
LFTsAST / ALT 5-10 x ULN* =
210-420 U/L, 240-480 U/L
≤ 42 U/L , ≤ 48U/L
Pancreatic Enzymes
Amylase, Lipase > 2-3 x ULN* 23-85 U/L, 0-160 U/L
Lipids
Triglyceride (TG) 8.49- 13.56 mmol/L
< 200 mg/dL
Cholesterol 1.6-2.0 X ULN < 200 mg/dL
* ULN = Upper Limit of Normal
23
Toxicity: Changing One Drug
Regimen: d4T/3TC/NVPd4T-related neuropathy or pancreatitis: Switch d4T to ZDVNVP-related rash or hepatotoxicity:
• Switch NVP to EFZ (except pregnancy)
• Switch NVP to PI’s (in cases of pregnancy or severe adverse effect)
Regimen: d4T/3TC/EFVEFZ-related persistent CNS toxicity: Switch EFZ to NVP
Regimen: ZDV/3TC/EFVZDV-related anemia or neutropenia: Switch ZDV to d4T
24
Co-morbidities
A change in clinical status of patients may mandate change in ARTPregnancy:
• If on EFV based regimen – change EFV to NVPOccurrence of active TB:
• If on NVP based regimen – change to EFV (with adjusted dose), to LPV/r, or SQV/r
25
Minimizing Viral Resistance
Never prescribe ARVs in the absence of adherence counseling and support
Work with patients and their families to minimize barriers to medication adherence
Never prescribe ARV monotherapy or dual therapy If ARV medications are to be discontinued, stop all
drugs at the same time
26
Minimizing Viral Resistance (2)
Do not prescribe ZDV (zidovudine) and d4T (stavudine) together (antagonistic)
Pay meticulous attention to other medications and treatments and their potential to interact with ARV therapies
Never add a single drug (alone) to a failing regimen
27
Improving Adherence and Enhancing QOL
Reduce pill burdenChanging to fixed dose combinationsReplace PIs with NNRTI’s or abacavir
Minimize food/water restrictions Revisit co-morbid conditions that might be interfering,
e.g. mental health; substance abuse Inquire about side effects that may have contributed to
poor adherence
28
Changing Regimen
When changing regimen due to treatment failure:Evaluate for resistance through resistance testing or
empiric decision-making based on clinical historyChange to an entirely new regimen, with at least one drug
from a new class
Anticipate some cross-resistance (e.g. ZDV and d4T)
Try to determine and correct reasons for failure of the first regimen (e.g. adherence issues)
29
First Line Regimen 2nd Line Regimen for Tx Failure
D4T or ZDV+
3TC+
NVP or EFV
ABC or TDF or ZDV (if not taken)+
DDI+
LPV/r or SQV/r OR NFV or IDV/r
Alternative Regimen
Source: Guideline for Use of Antiretroviral Drugs in Ethiopia. MOH, January 2005. p. 16
30
Changing Regimen (2)
Second-line therapy for patients with drug failure on d4T/3TC/nevirapine or efavirenz:
• ZDV + DDI + IDV/r or
• TDF +DDI + LPV/r
Second-line therapy for patients with drug failure on ZDV/3TC/nevirapine or efavirenz:
• TDF + DDI + IDV/r or
• TDF +DDI + LPV/r
Monitoring Therapy
32
First-Line Regimen: Laboratory Monitoring
Baseline: ALT and CD4 or TLC Additional lab monitoring varies with regimen
NVP: ALT/AST at 2, 4, 6, 8 weeks, 3 months, then q 6 months and symptom directed
EFV: symptom directed thereafter for ALT, pregnancy test at baseline for women of childbearing age
ZDV: CBC/diff at baseline, 2, 4, 8 and 12 wks, then q 3-6 months and symptom directed
Laboratory Monitoring GuidelineRegimen ART Lab Test Frequency
1 D4T/3TC/NVP ALT
TLC or CD4
Baseline, 2, 4, & 8 wks, then q 6 months & symptom directed for toxicity
Baseline & q 6 months
Other D4T/3TC/EFV
ZDV/3TC/EFV
ZDV/3TC/NVP
ALT
TLC or CD4
ALT
TLC or CD4
CBC + diff/ Hgb/Pltc
ALT
TLC or CD4
CBC + diff/ Hgb/Pltc
Symptom directed
Baseline & q 3-6 months
Symptom directed
Baseline & q 3-6 months
Baseline, 4, and 12 wks, & thereafter symptom directed
Baseline, 2, 4, & 8 wks, then q 6 months then q 6 months & symptom directed for toxicity
Baseline & q 3-6 months
Baseline, 4, and 12 wks, & thereafter symptom directed
Refer to slide at end of handbook. Source: Guideline for Use of Antiretroviral Drugs in Ethiopia. MOH, January 2005.
34
Second-Line Regimen: Laboratory Monitoring Baseline: CBC/diff, ALT, SCr and CD4 or TLC Other lab monitoring varies with regimen
ZDV: CBC/diff at baseline, 2, 4, 8, 12 wks, then q 3-6 months and symptom directed
DDI: amylase at baseline and symptoms of abdominal pain, CBC with diff and LFTs q 12 months
TDF: urine protein dipstick and SCr at baseline, 3 months and q 6 months, CBC/diff and AST/ALT q 12 months
PIs: lipids at baseline and q 12 months, AST/ALT at baseline, 3 months then q 6 months, fasting glucose at baseline, then q 12 months
Indinavir: urine dipstick for RBCs with symptoms of flank pain, SCr at baseline then q 6 months
Case Studies
Case 1
37
Case Study: Kasahun
Kasahun is a 25 year-old male (CD4 count 56) who presents to clinic for follow-up 2 weeks after starting ZDV, 3TC and NVP. He learned his HIV status two months ago, during a hospitalization with CNS toxoplasmosis. He is currently receiving treatment for toxoplasmosis and has tolerated his medication over the past two months
At diagnosis he had significant lower leg numbness and weakness due to INH therapy for TBPyridoxine 40 mg was started to replace his B-complex
vitamin. Why would this be necessary?
38
Case Study: Kasahun (2)
He had some nausea the first week on meds, which he has resolved by eating small meals before doses. He claims to take his medications every day as directed. He has lost weight and is now 51 kg
Today he presents complaining of a mildly itchy red rash over his trunk and arms which began 2 days ago. He says he feels tired all day. He proudly states that he has taken his NVP twice daily since his first day on medications
39
Case Study: Kasahun (3)
1. What do you think is occurring with Kasahun?
2. Should his ART regimen be changed?
3. What additional information would you like to know?
4. What are the laboratory tests that should be done at today’s visit to monitor Kasahun’s therapy?
40
Case Study: Kasahun Follow-up (4)
Laboratory ValuesWBC: 5.6 H/H: 6.9 / 27 LFTs: 31 / 26
How would you interpret these lab results? He has had only minor headaches over the past 3
weeks. What does this tell us? He does not have any other areas of the rash, oral
blisters, myalgias or fever. What should you do? Did he take NVP QD x 2 weeks, then increase to
BID?
41
Case Study: Kasahun (5)
He has not been having trouble remembering doses He has been taking doses with meals (breakfast and
dinner)
Peripheral neuropathy symptoms have improved However, he has been missing work due to fatigue
42
Case Study: Kasahun (6)
1. How would you interpret his results?
2. Would you change his ART?
3. How would you counsel Kasahun?
43
Case Study: Kasahun (7)
Follow up at 3 months shows:CD4 count = 110 (10%) cell/mm3Hemoglobin/Hematocrat = 13 / 38%WBC = 5.855 kgHe is tolerating medications except for occasional numbness
in lower extremities. His symptoms have somewhat improved over last 3 months. Occasional nausea after taking meds
Claims he is taking all his medications. He takes his morning dose at work during his break and takes his evening dose with dinner
44
Case Study: Kasahun (8)
Therapeutic goals are being metPatient energy increased and he’s feeling betterAppetite is good and he has gained 4 KgCD4 increasing (was 56/5% 2 months ago)H/H normalized
However, he reports side effects:If possible, decrease dose of stavudine to 30mg BID for
neuropathyEncourage food before doses
Case 2
46
Case Study: Yared
Yared is a 30 year-old man who has been stable on stavudine, lamivudine and nevirapine for the past four years
History: PCP pneumonia 4 years ago Today his CD4 cell count is 140 cells/mm3, his
previous CD4 count was 300 and his viral load has risen from undetectable levels to 50,000 copies/ml
He feels well and has no complaints today
47
Case Study: Yared (2)
1. What do you think is happening to Yared?
2. What additional information would you like to know?
3. Does he require a change in his regimen?
4. What possible regimen can you give to Yared, based on your local situation?
48
Case Study: Yared Follow-up (3)
Yared had been taking his medication as prescribed but missed doses recently while he was visiting his brother in Jimma
What are the factors to consider before starting a new regimen?
49
Case Study: Yared (4)
Side effectsEducate Yared on the potential side effects of each
potential regimen Patient preference
Yared is very fearful of the ABC hypersensitivity syndrome and would prefer to avoid ABC in his next regimen
Review drug-drug interactions Cost and sustainability Barriers to adherence
Plan ahead for changes in schedule, vacations, etc
50
Case Study: Yared (5)
He will begin TDF 300 mg qd +DDI 250 mg qd +LPV/r 3 caps bid
How will you monitor his therapy?ClinicalLaboratory
Does he have to take his DDI apart from LPV/r and/or tenofovir?
51
Key Points
Treatment failure occurs because of preexisting resistance, limited regimen potency, imperfect adherence, poor absorption, rapid elimination, or drug-drug interactions
Therapy should not be changed unless absolutely necessary
The main reasons for changing ART are treatment failure and drug toxicity
52
Key Points (2)
Other reasons for changing ART include problems with adherence or other medical conditions or illnesses
Ongoing laboratory monitoring is necessary to detect all side effects and to monitor success/failure of therapy